205 related articles for article (PubMed ID: 33869777)
1. Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review.
Tan Y; Ye Y; Chen L
Open Med (Wars); 2021; 16(1):553-557. PubMed ID: 33869777
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.
Li L; Lou A; Yu J
Ann Palliat Med; 2021 Jul; 10(7):8460-8466. PubMed ID: 34044548
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature.
Tan YW; Chen L; Zhou XB
World J Clin Cases; 2021 Jun; 9(17):4415-4422. PubMed ID: 34141809
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature.
Liu K; Bao JF; Wang T; Yang H; Xu BP
World J Clin Cases; 2022 Jun; 10(18):6198-6204. PubMed ID: 35949858
[TBL] [Abstract][Full Text] [Related]
5. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
Chen Y; Zhang H; Shi J; Wang T
Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
7. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
8. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
9. Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature.
Chen Y; Huang Z; Xing L; Meng X; Yu J
Front Oncol; 2020; 10():561. PubMed ID: 32411597
[No Abstract] [Full Text] [Related]
10. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.
Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J
Front Oncol; 2023; 13():1280208. PubMed ID: 38090483
[TBL] [Abstract][Full Text] [Related]
11. Immune-Related Colitis Induced by Camrelizumab: A Case Report.
Cheng S; Yang Y; Yu J; Chen W; Li X
J Inflamm Res; 2023; 16():1727-1731. PubMed ID: 37096128
[TBL] [Abstract][Full Text] [Related]
12. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
13. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation.
Wei Z; Yang X; Ye X
J Cancer Res Ther; 2020 Sep; 16(5):1191-1195. PubMed ID: 33004770
[TBL] [Abstract][Full Text] [Related]
14. Successful liver transplantation for acute sickle cell intrahepatic cholestasis: A case report and review of the literature.
Alkhayyat M; Saleh MA; Zmaili M; Sanghi V; Singh T; Rouphael C; Simons-Linares CR; Romero-Marrero C; Carey WD; Lindenmeyer CC
World J Hepatol; 2020 Mar; 12(3):108-115. PubMed ID: 32231764
[TBL] [Abstract][Full Text] [Related]
15. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review.
Wan Y; Wang Z; Yang N; Liu F
Front Oncol; 2022; 12():911961. PubMed ID: 35865468
[TBL] [Abstract][Full Text] [Related]
18. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
[TBL] [Abstract][Full Text] [Related]
19. Ductopenia and cirrhosis in a 32-year-old woman with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature.
Tan YW; Ji HL; Lu ZH; Ge GH; Sun L; Zhou XB; Sheng JH; Gong YH
World J Gastroenterol; 2018 Nov; 24(41):4716-4720. PubMed ID: 30416319
[TBL] [Abstract][Full Text] [Related]
20. Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma.
Yang Y; Li J; Till BG; Wang J; Zhang B; Wang H; Huang H; Li T; Gao Q; Li H; Wang Z
Front Oncol; 2021; 11():728253. PubMed ID: 34778042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
